<DOC>
	<DOCNO>NCT00197223</DOCNO>
	<brief_summary>As result recent supply shortages U.S. , well anticipated increase demand come year , GSK Biologicals pursue licensure Fluarix U.S. accelerate approval process ; marketing approval likely granted start clinical trial . GSK propose support U.S. licensure Fluarix confirmatory post-marketing study . The purpose study evaluate efficacy single dose Fluarix prevent influenza adult 2005/2006 Influenza season .</brief_summary>
	<brief_title>Post-marketing Study Evaluate Efficacy Influenza Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female age , include , 18 64 year age time vaccination . Written inform consent obtain subject . Availability follow phone study period . Female subject must nonchildbearing potential , i.e . either surgically sterilize one year postmenopausal . If subject childbearing potential , must abstinent use adequate contraceptive precaution 30 day prior vaccination . She must also negative pregnancy test study entry must agree continue precaution two month vaccination . History hypersensitivity previous dose influenza vaccine . History allergy reaction likely exacerbate component vaccine include egg , chicken protein , formaldehyde , thimerosal , gentamicin sulfate sodium deoxycholate . Acute disease time enrollment . ( Acute disease define presence moderate severe illness without fever ) . All vaccine administer person minor illness diarrhea , mild upper respiratory infection without lowgrade febrile illness , i.e . Oral temperature &lt; 37.5Â°C ) . Pregnancy Chronic disorder pulmonary cardiovascular system , include asthma History require regular medical followup hospitalization precede year chronic metabolic disease ( include diabetes mellitus ) , renal dysfunction , hemoglobinopathy , immunosuppression ( include immunosuppression cause medication human immunodeficiency virus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>